Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
Akihito KawazoeRui-Hua XuPilar García AlfonsoMaria PasshakHao-Wei TengArdaman ShergillMahmut GümüşCamilla QvortrupSebastian StinzingKathryn TownsTae Won KimKai-Keen ShiuJuan CundomSumitra AnandaAndrey LebedinetsRong FuRishi JainDavid AdelbergVolker HeinemannTakayuki YoshinoElena Elez Fernandeznull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
In patients with pMMR or not MSI-H mCRC that had progressed on previous therapy, there was no statistically significant improvement in OS after lenvatinib plus pembrolizumab treatment versus SOC. No new safety signals were observed.